International Breast Cancer Study Group trials

Area of Science:

• Oncology
• Clinical Trials
• Breast Cancer Research

Background:

• The International Breast Cancer Study Group (IBCSG), established in 1978, has conducted extensive clinical trials.
• The group has accrued over 12,000 patients across multiple generations of studies.
• IBCSG trials focus on critical biological questions and risk-adapted patient stratification.

Purpose of the Study:

• To evaluate the efficacy of various chemotherapy and endocrine therapy combinations in breast cancer.
• To determine optimal treatment durations and timing for different patient subgroups (premenopausal/postmenopausal, node-negative/node-positive).
• To explore novel therapeutic strategies including ovarian suppression and high-dose chemotherapy regimens.

Main Methods:

• Multi-generational randomized clinical trials involving international member institutions.
• Comparison of different chemotherapy regimens (e.g., CMF) and endocrine therapies (tamoxifen, toremifene).
• Investigation of treatment timing (perioperative vs. conventionally timed) and adjuvant strategies.

Main Results:

• Combined chemoendocrine therapy is superior to endocrine therapy alone or no therapy for node-positive postmenopausal patients.
• Six cycles of CMF chemotherapy are as effective as seven cycles initiated perioperatively.
• Early CMF chemotherapy followed by tamoxifen shows benefit in postmenopausal patients, while late reintroduction may be detrimental.
• Six initial cycles of chemotherapy are superior to three in premenopausal patients.

Conclusions:

• Chemoendocrine therapy and optimized chemotherapy timing significantly improve outcomes in node-positive breast cancer.
• Current research focuses on optimizing treatment gaps, comparing anti-estrogens, and evaluating ovarian suppression.
• Future trials emphasize inter-group collaboration for rapid evaluation of new breast cancer therapies.